The worldwide merger of Glaxo and SmithKline Beecham has sparked off an interesting twist on the Indian horizon. SmithKline is present in India in two segments, one in pharmaceuticals (as SmithKline Pharma) and the other in the malted beverage segment (as SmithKline Consumer Healthcare). While it makes sense for both Glaxo and SmithKline to merge their pharma operations, the business profile of SmithKline Consumer (SBCH) doesn’t quite fit into this jigsaw. So what do they do with SBCH?
There are several possibilities. For one, they can quite simply merge the company into the group and let it run as an independent entity. But this will take a little bit away from Glaxo’s pharma focus for which it is known. Earlier, Glaxo had sold off its Farex brand (baby food) to Heinz because it did not fit their business profile.
A second possibility also exists. SBCH operates in Rs 7 bn malted food drink market (estimated at 60,000 tonnes). The market can broadly be classified into white beverages (65%), brown beverages (35%) and soya-based beverages (negligible). SmithKline Consumer commands 65% of this market with its brands Horlicks and Boost. If Glaxo-SmithKline combine decide to sell off this malted beverage giant, the picture could be interesting.
Among the first one to show interest should be India’s No. 1 FMCG company Hindustan Lever Limited (HLL). The company is facing stagnant growth in turnover and pressure on margins. It is focusing on the food segment for improving its margins. It doesn’t have a presence in the malted and health beverage segment and the buyout of SBCH will give it a ready entry in this segment.
Another likely suitor seems to be Nestle. Nestle is India’s third largest food product company. It has a dominant presence in the culinary segment. However, Nestle already has presence in the brown beverage segment with ‘Milo’. Incidentally, Milo is the largest chocolate energy drink in the world. But Nestle introduced this brand only in 1997 and Milo has not made a significant impact in the Indian market. So for Nestle also, it makes sense to buyout SBCH (if its up for sale), as SBCH’s Horlicks (white beverage) will complement Milo (brown beverage). It will make it the undisputed king of India’s malted beverage market.
Till now, the malted drinks were used as milk substitutes and taste modifiers. The market is now skewed towards nutritional and nourishment value. The penetration rate is poor, as it is an expensive product. However, with competitive pressures on children on the rise, an increasing number of households (mostly urban) are buying these products for their children, based on health platform.
So it is an interesting scenario. SBCH, if put on the block will see a lot of competing suitors apart from Nestle and HLL. But these two companies seem like the frontrunners in that future race, as apart from the will to buy, these companies also have the necessary cash to back it up.
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407